Novartis AG entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion on May 2, 2024. Under the terms of the agreement, Novartis will make an upfront payment of $1 billion and additional $750 million in payments upon completion of pre-specified milestones. The transaction is subject to customary closing conditions.

Centerview Partners LLC served as financial advisor, and Laura Umbrecht Gulick, Kingsley L. Taft, Zhenghui (Alan) Wang, Arman Oruc, Elliot Silver, Sarah M. Bock, Daniel S. Karelitz, Richard L. Matheny III, Julie Tibbets, Matt Wetzel, Jennifer Merrigan Fay, Ai Tajima and J. Scott Zilora of Goodwin Procter as legal advisor to Mariana Oncology on the transaction.